 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Saturday
Creatine, Minocycline May Warrant Further Study in PD
Results of a randomized futility trial suggest that both creatine and minocycline could be considered for definitive phase 3 trials to see whether they may alter the course of Parkinson's disease (PD).
A futility trial is not meant to assess efficacy per se but to rule out the possibility that use of these agents would be futile, said Wendy Galpern, MD, PhD, a program director in clinical trials at the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Galpern is involved with the National Institutes of Health (NIH) Exploratory Trials in Parkinson’s Disease (NET-PD), an NINDS-funded effort.
"The terminology is that we failed to find either agent futile, so basically they were both identified as worth considering for a larger trial," Dr. Galpern told Medscape. However, she stressed, "It doesn't mean a patient should go out and take either agent; it means they could be considered for a further, definitive trial."
Some of their further analyses gave an edge to creatine, including apparently better tolerability, she noted.
Their study was presented November 1 at the Movement Disorders Society's 10th International Congress on Parkinson's Disease and Movement Disorders in Kyoto, Japan. First author on the trial was Barbara C. Tilley, PhD, from the Medical University of South Carolina in Charleston, on behalf of the NINDS NET-PD investigators....
In a related finding, published in the November 8 issue of the Journal of Neuroscience (Peng J et al. 2006;26:11644-11651), researchers at the Buck Institute for Age Research, in Novato, California, report data indicating that the degeneration of midbrain dopaminergic neurons in weaver mice, a mouse model of PD, is mediated by neuroinflammation.
Administration of minocycline to these mice — which, as these researchers point out, has been shown to have neuroprotective properties in other neurodegenerative disease models such as amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis — also resulted in a decrease in the degeneration of dopaminergic neurons. At 3 weeks of age, treated mice had a 30% loss of neurons in the substantia nigra, compared with a 50% loss seen in weaver mice not receiving minocycline.
"Currently, by the time humans are diagnosed with Parkinson's disease, they have already lost 60% of their dopamine-producing neurons," senior author Julie K. Anderson, PhD, said in a statement from the Buck Institute. "Anti-inflammatory agents would likely be maximally effective if taken before symptoms appear, to halt disease progression." MORE
Results of a randomized futility trial suggest that both creatine and minocycline could be considered for definitive phase 3 trials to see whether they may alter the course of Parkinson's disease (PD).
A futility trial is not meant to assess efficacy per se but to rule out the possibility that use of these agents would be futile, said Wendy Galpern, MD, PhD, a program director in clinical trials at the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Galpern is involved with the National Institutes of Health (NIH) Exploratory Trials in Parkinson’s Disease (NET-PD), an NINDS-funded effort.
"The terminology is that we failed to find either agent futile, so basically they were both identified as worth considering for a larger trial," Dr. Galpern told Medscape. However, she stressed, "It doesn't mean a patient should go out and take either agent; it means they could be considered for a further, definitive trial."
Some of their further analyses gave an edge to creatine, including apparently better tolerability, she noted.
Their study was presented November 1 at the Movement Disorders Society's 10th International Congress on Parkinson's Disease and Movement Disorders in Kyoto, Japan. First author on the trial was Barbara C. Tilley, PhD, from the Medical University of South Carolina in Charleston, on behalf of the NINDS NET-PD investigators....
In a related finding, published in the November 8 issue of the Journal of Neuroscience (Peng J et al. 2006;26:11644-11651), researchers at the Buck Institute for Age Research, in Novato, California, report data indicating that the degeneration of midbrain dopaminergic neurons in weaver mice, a mouse model of PD, is mediated by neuroinflammation.
Administration of minocycline to these mice — which, as these researchers point out, has been shown to have neuroprotective properties in other neurodegenerative disease models such as amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis — also resulted in a decrease in the degeneration of dopaminergic neurons. At 3 weeks of age, treated mice had a 30% loss of neurons in the substantia nigra, compared with a 50% loss seen in weaver mice not receiving minocycline.
"Currently, by the time humans are diagnosed with Parkinson's disease, they have already lost 60% of their dopamine-producing neurons," senior author Julie K. Anderson, PhD, said in a statement from the Buck Institute. "Anti-inflammatory agents would likely be maximally effective if taken before symptoms appear, to halt disease progression." MORE